A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in G1 Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 278,700 shares of GTHX stock, worth $1.99 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
278,700
Previous 89,100 212.79%
Holding current value
$1.99 Million
Previous $384,000 65.36%
% of portfolio
0.0%
Previous 0.0%

Shares

25 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$2.2 - $4.98 $499 - $1,130
227 Added 1891.67%
239 $0
Q1 2024

May 15, 2024

SELL
$2.1 - $4.83 $92,303 - $212,297
-43,954 Reduced 99.97%
12 $0
Q4 2023

Feb 14, 2024

SELL
$1.12 - $3.73 $108,474 - $361,257
-96,852 Reduced 68.78%
43,966 $134,000
Q3 2023

Nov 14, 2023

SELL
$1.22 - $2.67 $1,329 - $2,910
-1,090 Reduced 0.77%
140,818 $202,000
Q2 2023

Aug 14, 2023

BUY
$2.46 - $3.14 $98,756 - $126,055
40,145 Added 39.45%
141,908 $353,000
Q1 2023

May 15, 2023

SELL
$2.57 - $8.16 $496,421 - $1.58 Million
-193,160 Reduced 65.5%
101,763 $272,000
Q4 2022

Feb 14, 2023

BUY
$5.19 - $13.5 $1.01 Million - $2.62 Million
193,835 Added 191.75%
294,923 $1.6 Million
Q3 2022

Nov 14, 2022

SELL
$5.17 - $16.99 $1.19 Million - $3.92 Million
-230,806 Reduced 69.54%
101,088 $1.26 Million
Q2 2022

Aug 15, 2022

BUY
$4.04 - $8.51 $156,986 - $330,681
38,858 Added 13.26%
331,894 $1.64 Million
Q1 2022

May 16, 2022

BUY
$7.6 - $11.02 $194,795 - $282,453
25,631 Added 9.59%
293,036 $2.23 Million
Q4 2021

Feb 14, 2022

BUY
$10.16 - $16.17 $2.52 Million - $4.01 Million
247,871 Added 1268.92%
267,405 $2.73 Million
Q3 2021

Nov 15, 2021

SELL
$13.16 - $22.47 $297,258 - $507,552
-22,588 Reduced 53.63%
19,534 $262,000
Q2 2021

Aug 16, 2021

SELL
$19.57 - $26.32 $670,350 - $901,565
-34,254 Reduced 44.85%
42,122 $924,000
Q1 2021

May 17, 2021

SELL
$17.58 - $32.59 $1.79 Million - $3.32 Million
-102,004 Reduced 57.18%
76,376 $1.84 Million
Q4 2020

Feb 16, 2021

SELL
$10.99 - $20.4 $905,400 - $1.68 Million
-82,384 Reduced 31.59%
178,380 $3.21 Million
Q3 2020

Nov 16, 2020

BUY
$11.55 - $23.75 $2.09 Million - $4.29 Million
180,673 Added 225.58%
260,764 $3.01 Million
Q2 2020

Aug 14, 2020

SELL
$9.57 - $24.37 $432,353 - $1.1 Million
-45,178 Reduced 36.06%
80,091 $1.94 Million
Q1 2020

May 15, 2020

SELL
$9.07 - $26.32 $37,250 - $108,096
-4,107 Reduced 3.17%
125,269 $1.38 Million
Q4 2019

Feb 14, 2020

BUY
$20.54 - $31.0 $2.3 Million - $3.47 Million
111,852 Added 638.28%
129,376 $3.42 Million
Q3 2019

Nov 14, 2019

SELL
$22.78 - $40.58 $126,930 - $226,111
-5,572 Reduced 24.13%
17,524 $399,000
Q2 2019

Aug 14, 2019

SELL
$16.03 - $31.1 $4.09 Million - $7.94 Million
-255,412 Reduced 91.71%
23,096 $708,000
Q1 2019

May 15, 2019

BUY
$14.4 - $21.45 $1.54 Million - $2.29 Million
106,653 Added 62.06%
278,508 $0
Q4 2018

Feb 14, 2019

BUY
$16.51 - $51.33 $2.76 Million - $8.58 Million
167,210 Added 3599.78%
171,855 $3.29 Million
Q3 2018

Nov 13, 2018

SELL
$43.15 - $67.97 $158,748 - $250,061
-3,679 Reduced 44.2%
4,645 $0
Q1 2018

May 11, 2018

BUY
$19.05 - $41.76 $158,572 - $347,610
8,324 New
8,324 $308,000

Others Institutions Holding GTHX

About G1 Therapeutics, Inc.


  • Ticker GTHX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 42,746,800
  • Market Cap $306M
  • Description
  • G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/...
More about GTHX
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.